Beta Bionics Inc’s recent filing unveils that its Officer Sean Saint acquired Company’s shares for reported $61524.0 on Jun 02 ’25. In the deal valued at $17.89 per share,3,439 shares were bought.
Then, Hopman Mark sold 868 shares, generating $15,529 in total proceeds. Upon selling the shares at $17.89, the Chief Commercial Officer now owns 34,132 shares.
Before that, Russell Steven Jon sold 1,039 shares. Beta Bionics Inc shares valued at $18,588 were divested by the Chief Medical Officer at a price of $17.89 per share. As a result of the transaction, Russell Steven Jon now holds 72,032 shares, worth roughly $1.08 million.
Truist initiated its Beta Bionics Inc [BBNX] rating to a Buy in a research note published on June 16, 2025; the price target was $26. A number of analysts have revised their coverage, including Lake Street’s analysts, who began to cover the stock in mid June with a ‘”a Buy”‘ rating. Wolfe Research began covering BBNX with “an Outperform” recommendation on May 30, 2025. Goldman started covering the stock on May 30, 2025. It rated BBNX as “a Neutral”.
Price Performance Review of BBNX
On Tuesday, Beta Bionics Inc [NASDAQ:BBNX] saw its stock jump 4.62% to $14.96. Over the last five days, the stock has gained 19.39%. Nevertheless, the stocks have fallen -36.69% over the past one year.
Levels Of Support And Resistance For BBNX Stock
The 24-hour chart illustrates a support level at 14.26, which if violated will result in even more drops to 13.57. On the upside, there is a resistance level at 15.36. A further resistance level may holdings at 15.76.
How much short interest is there in Beta Bionics Inc?
A steep rise in short interest was recorded in Beta Bionics Inc stocks on 2025-06-30, growing by 0.77 million shares to a total of 4.9 million shares. Yahoo Finance data shows the prior-month short interest on 2025-05-30 was 4.13 million shares. There was a rise of 15.69%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on February 24, 2025 when Stifel began covering the stock and recommended ‘”a Buy”‘ rating along with a $25 price target.
